

Pursuant to the provisions of article 226 of the Law 6/2023, of March 17, on Securities Markets and Investment Services, Grifols S.A. ("**Grifols**" or the "**Company**") hereby informs about the following

## INSIDE INFORMATION

The Board of Directors of Grifols, S.A. has unanimously approved that its fully owned subsidiary Grifols Biotest Holdings GmbH submits a public delisting purchase offer to the shareholders of Biotest AG ("**Biotest**"). Thus, Grifols Biotest Holdings GmbH announces today its decision to purchase by way of a public delisting purchase offer all no-par bearer common shares of Biotest and all non-voting bearer preferred shares in Biotest and its intention to offer EUR 43.00 per each common share and EUR 30.00 per each preferred share. Further, Grifols and Biotest have agreed that no later than ten (10) workdays prior to expiration of the deadline for accepting the delisting offer they will apply for the cancellation of the admission of the shares of Biotest to trading on the Frankfurt Securities Exchange.

The terms and conditions of the delisting offer will be communicated in the offer document ("**Offer Document**") to be prepared by Grifols and to be examined by the German federal financial supervisory authority, the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) in the coming weeks.

Once the Offer Document is approved by BaFin, it will be published in accordance with applicable laws and will also be reported as inside information, and its contents will be published on Grifols' website.

In Barcelona, on 31 March 2025.

---

Nuria Martín Barnés  
Secretary to the Board of Directors